Berlin - Delayed Quote EUR

Exelixis Inc (EX9.BE)

Compare

31.53

+0.12

+(0.38%)

At close: January 31 at 8:01:01 AM GMT+1

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for EX9.BE

Here's Why Exelixis (EXEL) is a Strong Value Stock

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Exelixis Inc (EX9.BE)

Comparisons

Indicators

Technicals

Corporate Events

-1.65%

-1.22%

16.69%

49.50%

-1.22%

57.77%

99.81%

118.96%

Recent News: EX9.BE

Here's Why Exelixis (EXEL) is a Strong Value Stock

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?

Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns

Revenues, Treatment Pipeline Driving Exelixis Higher

EXEL vs. TECH: Which Stock Is the Better Value Option?

What Makes Exelixis (EXEL) an Investment Bet?